Insider Trading July 10, 2026 01:27 PM

VIVOS Inc President Brad Weeks Acquires Additional Shares Amid Stock Surge

Insider buying activity highlights executive confidence as the medical instruments firm navigates valuation debates and profitability pressures.

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
RDGL

Brad Allan Weeks, serving as president of VIVOS Inc, has expanded his direct ownership in the company through recent equity purchases. The transactions, documented in a recent Securities and Exchange Commission filing, reveal a cumulative investment of $4,800. This insider activity unfolds against a backdrop of significant short-term price appreciation for the stock, which has climbed 45% over the preceding week. Despite the bullish insider signal, external analysis suggests the shares may be trading above fundamental value, placing the company in a contested position within the surgical and medical instruments sector.

VIVOS Inc President Brad Weeks Acquires Additional Shares Amid Stock Surge
RDGL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • VIVOS Inc President Brad Weeks purchased a total of 60,000 shares at $0.08 per share, bringing his direct ownership to 999,235 shares.
  • The stock has surged 45% in the past week, yet analysis suggests the shares may be overvalued relative to fundamentals.
  • The company operates in the surgical and medical instruments sector, facing profitability pressures with $80,000 in trailing twelve-month revenue against a $40.4 million market cap.

Brad Allan Weeks, the president of VIVOS Inc, has increased his direct equity position in the company through a series of recent stock acquisitions. According to a filing submitted to the Securities and Exchange Commission, the purchases were executed over a two-day period, reflecting a deliberate accumulation of shares.

On July 9, 2026, Mr. Weeks acquired 48,000 shares of VIVOS Inc common stock at a unit price of $0.08. The following day, July 10, 2026, he purchased an additional 12,000 shares, again at $0.08 per share. These transactions, all executed directly, brought the total value of his recent purchases to $4,800.

Following these acquisitions, Mr. Weeks holds a total of 999,235 shares of VIVOS Inc common stock, identified by the ticker symbol RDGL. This insider buying activity occurs as the stock has experienced a notable 45% surge over the past week. However, concurrent analysis by InvestingPro indicates that the shares may be overvalued at current trading levels, which places RDGL on a list of stocks considered to be trading above intrinsic value.

The company operates within the surgical and medical instruments industry and maintains a market capitalization of $40.4 million. Financial data reveals significant operational challenges, with the company reporting revenue of only $80,000 over the last twelve months. These figures highlight ongoing profitability concerns that contrast with the recent price momentum.

Key Points

  • VIVOS Inc President Brad Weeks purchased a total of 60,000 shares at $0.08 per share, bringing his direct ownership to 999,235 shares.
  • The stock has surged 45% in the past week, yet analysis suggests the shares may be overvalued relative to fundamentals.
  • The company operates in the surgical and medical instruments sector, facing profitability pressures with $80,000 in trailing twelve-month revenue against a $40.4 million market cap.

Risks and Uncertainties

  • Valuation Risk: Independent analysis suggests the shares may be overvalued, indicating a potential disconnect between price action and underlying business performance.
  • Profitability Risk: The company reported minimal revenue of $80,000 over the last twelve months, raising questions about sustainable earnings and operational scaling.

Risks

  • Valuation Risk: Independent analysis suggests the shares may be overvalued, indicating a potential disconnect between price action and underlying business performance.
  • Profitability Risk: The company reported minimal revenue of $80,000 over the last twelve months, raising questions about sustainable earnings and operational scaling.

More from Insider Trading

Culp Inc. CEO Robert Culp IV Acquires $9,217 in Company Shares Amid Financial Recovery Jul 10, 2026 UroGen Pharma CMO Schoenberg Executes Final $400K Share Sale Under Pre-Arranged Plan Jul 10, 2026 Globalfoundries Strategy Officer Michael Hogan Sells Shares Under Pre-Arranged Plan Jul 10, 2026 Horizon Kinetics Acquires Additional TPL Shares Amid Strong Q1 Performance and Strategic Chevron Partnership Jul 10, 2026 Horizon Kinetics Increases RCG Position with $2,283 Acquisition Jul 10, 2026